BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Edelweiss maintains buy on Cadila Healthcare
Cadila Healthcare (CDH) has received approval for gLialda, the first and one of the most significant filings from Moraiya. Importantly, this development lends validation to CDH's other complex generic filings, especially gAsacol HD and others like gToprol XL, gPrevacid ODT and transdermals.Launches like these, we believe will lead to best-in-class US growth among peers, and drive around 44 per cent earnings CAGR for CDH over FY17-19E.